

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06733675

Status	RECRUITING
Phase	Phase 1
Sponsor	Basilea Pharmaceutica
Enrollment	46 participants

Key Eligibility Criteria

Inclusion (4)

- Healthy adult male or female, between 18 and 55 years of age
- Body mass index e 18 and d 32 kg/m²
- Laboratory values meeting defined laboratory ranges
- Males or non-pregnant, non-lactating females

Exclusion (3)

- History of any hypersensitivity reaction following administration of a cephalosporin, penicillin, or other β -lactam antibacterial drug
- Any acute illness or surgery within the past 3 months determined by the investigator to be clinically relevant
- Positive alcohol, drug or tobacco use/test

Locations (1 total)

ICON, Clinical Research Phase I Unit, Lenexa, Kansas, United States